Occam Places Mark McDonough as CEO of ChromaCode
ChromaCode, a private, California-based molecular diagnostics company with founders out of Illumina, Google[x], and Luminex, has appointed Mark McDonough as CEO. Investors include NEA, Northpond Ventures, Vensana Capital, and Adjuvant Capital.
Mark is an accomplished, commercially-oriented serial CEO with more than two decades of achievement in molecular diagnostics. Most recently, he was CEO of PierianDx, a private, genomic SaaS solution provider in the cancer diagnostic space. Earlier, Mark served as CEO of CombiMatrix, a public company and leader in high-complexity reproductive health testing. He orchestrated that company’s sale to Invitae in 2017.
This is Occam’s second Dx CEO placement in a matter of months. Last year, Dave Mullarkey was appointed CEO of ClearNote Health, a Stephen Quake company.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.